






Time	Session Title	Poster/Oral Number	Title	Author	Scan for More Information
Sun 14 Apr Moderated: 5:45 - 6:45 PM	Poster Session 2 Location: Exhibition Hall and Main Foyer	SUN-049	Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Patients With Immunoglobulin A Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)	Preciado P, et al	
		SUN-042	Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy: Preliminary Findings From the SPARTAN Trial	Cheung CK, et al	
		SUN-048	Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases	Komers R, et al	
		SUN-045	Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety	Hendry B, et al	
Mon 15 Apr Presentation: 3:35 - 3:45 PM	Late Breaking Clinical Trials Session Location: Hall A	MON-296	Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy (IgAN): Subgroup Analysis of 2-Year Results From the Pivotal Phase 3 PROTECT Trial	Barratt J, et al	
Moderated: 5:45 - 6:45 PM	Poster Session 3 Location: Exhibition Hall and Main Foyer	MON-296	Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy (IgAN): Subgroup Analysis of 2-Year Results From the Pivotal Phase 3 PROTECT Trial	Barratt J, et al	